Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

1win and David Warner Launch Charitable #1win1000hits Challenge

1win , in partnership with cricket star David Warner, is excited to launch the #1win1000hits challenge — a charitable flashmob aimed at raising awareness of social issues and promoting support for those in need. Warner started the challenge by posting a high-pro Swing for Charity  to invite everyone to join the cause. With each new #1win1000hits video, 1win will increase its monetary donation to non-profit organizations.“Through this campaign, we aim to unite people worldwide for a fun and

LiveCasinoRank reviews Evolution's Newest Game Show: Lightning Storm

November 15, 2024- LiveCasinoRank, a leading website specializing in reviewing online live dealer casinos and covering various aspects of live dealer gambling, today provides an in-depth analysis of Evolution’s new live game show. As the popularity of live casino games rises, the LiveCasinoRank team remains dedicated to delivering accurate and relevant information tailored to live casino players. To read or check out trending games in live casinos click here .Innovating the Live Casino Game Show World Evolution Gaming announces its most

Director/PDMR Shareholding

15 November 2024 10:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announces that it was notified on 14 November 2024 that Pascal Soriot, Chief Executive Officer, purchased 20,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 November 2024, as set out below. PDMR Position Nature of the transaction Quantity PricePascal Chief Purchase of Ordinary Shares  20,000 GB£102.03Soriot Executive Officer Further details are set out in the attached notification, made in

Reminder: Invitation to DNB’s Capital Markets Day – 19 November 2024

DNB is pleased to invite you to the Group's Capital Markets Day. Date: Tuesday 19 November 2024 Time: 12:00 pm - 2:00 pm GMT. Registration and lunch from 11:00 am - 12:00 pm GMT Location: DNB Bank ASA London Office, 8th Floor, The Walbrook Building, 25 Walbrook, London EC4N 8AF  We will present an update on financial targets and strategic topics. In addition, our largest customer segments will provide a more detailed update.  Speakers at the CMD will be: -    Kjerstin R. Braathen, CEO -    Ida Lerner, CFO -    Maria Ervik Løvold, Group EVP Personal Banking -    Rasmus

DANISH FRONT-RUNNERS SIGN MILESTONE AGREEMENT TO DRIVE SUSTAINABLE AVIATION TRANSFORMATION

In a landmark move towards a sustainable aviation industry, SAS, Copenhagen Infrastructure Partners, Copenhagen Airport, and Aalborg Airport have signed a collaboration agreement to form a joint and united front, supporting Danish production of Sustainable Aviation Fuel (eSAF).This partnership aims to accelerate the important transformation of the aviation industry, positioning Denmark as a key player in the effort toward environmentally responsible aviation. It aspires to create public awareness and regulatory support that can help accelerate the green transition and showcases how it is

Bulletin from the Extraordinary General Meeting of Metacon AB (publ)

Metacon AB (publ), corporate identity number 556724-1616 (the "Company"), has held an Extraordinary General Meeting today, 15 November 2024 at 10:00 CET, at Advokatfirman Schjødt, Hamngatan 27, Stockholm. The Extraordinary General Meeting made the following resolutions. Amendments of the articles of association The Extraordinary General Meeting resolved, in accordance with the board of directors' proposal, to amend § 4 and § 5 in the articles of association. Following the amendments of § 4 and § 5 in the articles of association, the Company's share capital shall amount to at least SEK

Fenniarail OY Evaluates RMD’s Rear-View Camera

Currently, tests are underway for RMD’s rear-view camera at Finnish company Fenniarail, with evaluations set to continue until the end of February 2025.Fenniarail, a private Finnish company founded in 2009, emerged two years after Finland's rail freight market was opened to competition in 2007. The company provides efficient freight solutions across Finland's railway network and operates a fleet consisting of six Dr18 diesel locomotives and one Vectron electric locomotive. Two additional Vectron locomotives are expected to be delivered by the end of 2025. Enhanced Shunting Efficiency

Real-Time Excitement: Casinoble Brings In-Play Betting to Canadian Fans

Toronto, Canada — November 15, 2024 — Casinoble , a leading name in online gaming, is setting a new standard for Canadian sports fans with the launch of its advanced in-play betting platform. With in-play betting rapidly growing in popularity, Casinoble’s commitment to offering real-time, interactive options is transforming how Canadians engage with their favorite sports, from hockey and basketball to football and beyond.The Ultimate Real-Time Experience Casinoble’s in-play betting platform offers Canadians an immersive, moment-to-moment betting experience,

Lehto Group Plc, inside information: Information about Lehto's energy construction business and the company's intention to apply for the transfer of share trading to the First North Growth Market

Lehto Group PlcInsider information15 November 2024 at 11.00 (Finnish time)Lehto Group Oyj ("Lehto" or "Company") has previously announced on 29 May 2024 that it will focus its business on real estate energy solutions and electricity storages ("Energy construction business"). The company has also reported on the change in business direction in the January-June 2024 half-year report published on August 1, 2024. Energy construction business in short The energy construction business is based on the utilization of electricity storages in balancing the production and demand of the

Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical

As part of the ASSET innovation partnership led by Diamyd Medical, the Leading Healthcare Foundation organizes a conference on November 26, 2024, in Stockholm, Sweden, on the future of Type 1 Diabetes screening and treatment. The conference is co-sponsored by Sanofi.The event gathers key stakeholders, including patient organizations, healthcare professionals, researchers, and regulators, to explore the practical implementation of precision and preventive medicine in Type 1 Diabetes care. The conference will feature a keynote lecture by Prof. Chantal Mathieu, President of the European

Irisity Awarded 5th Year Renewal of Perimeter Security Contract in the UK

Gothenburg, Sweden – November 15th, 2024 – Irisity AB (publ), a provider of AI-driven video data management software, reports a renewal of a perimeter security contract with a UK-based home appliance manufacturer. It is an Annual Recurring Revenue (ARR) contract valued at more than MSEK 1.7, marking the fifth year of delivering a perimeter security SaaS deployment in partnership with a UK-based integration partner.  The contract began in November 2020, with yearly renewals. From an initial deployment of six cameras, the project continued to grow, expanding to 661 cameras by December 2023.

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 247 – 15 NOVEMBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 235/24 and 237/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Therese Möllevinge, Head of Investor Relations, tel.: +45 41 37 16 38, e-mail: thm@norden.com Isabella Zaugg Hansen, Investor Relations Manager, tel.: +45 27 62 90 96, e-mail: izh@norden.com

How to Play Online Bingo: A Beginner's Guide

Online bingo has become a popular pastime, offering the excitement of traditional bingo with the convenience of playing from home. If you're new to online bingo, this guide will help you get started and enjoy the game.Understanding the Basics At its core, bingo is a game of chance where players mark off numbers on a card as they are called out. The objective is to complete a specific pattern, such as a line or a full house, and be the first to complete the pattern and shout "Bingo!" to win. Understanding Bingo Cards In online bingo, you'll play with a digital bingo card. Each card

EQL Pharma's CBDO increases his holding in the company

EQL Pharma's Chief Business Development Officer (CBDO), Carl Lindgren, increases his shareholding in the company. On November 14[th], Carl Lindgren has bought 10,000 shares in the Company at an average price of SEK 60.00, a transaction totalling SEK 600,000. The trades were made outside the Stock Market and the shares were bought from the major owner Fårö Capital AB, related to Christer Fåhraeus who is Chairman of the board of EQL Pharma. After the purchases, Lindgren owns a total of 60,000 shares and 100,000 warrants in EQL Pharma."EQL is an entrepreneurial company in rapid and profitable

Cavendish Hydrogen ASA: Notice of extraordinary general meeting

Oslo, 15 November 2024: Based on a request from shareholders in accordance with section 5-7 (2) of the Norwegian Public Limited Liability Companies Act, the Board of Directors of Cavendish Hydrogen ASA ("Cavendish", OSE: CAVEN) calls for an extraordinary general meeting to be held on Friday, 6 December 2024 at 10:00 CET (the "EGM").The notice of the EGM, including the shareholders' proposed agenda item regarding Board election, is attached to this notice and available on https://cavendishh2.com/, and will be sent to Cavendish's shareholders with known addresses. The Company's Nomination

Q1 Interim Report July 2024 – September 2024

OPENING REMARKS   The first quarter of the fiscal year 2024-2025 has been productive for Hamlet Biopharma. As summarized in the recently published Annual Report 2023-2024, significant clinical progress has been made in three different clinical areas - bladder cancer, recurrent acute cystitis and bladder pain. We are proud to have taken the investigational new drug Alpha1H from discovery, through the drug development process to the clinic. We are also proud to have identified new clinical indications for the IL-1 receptor antagonist anakinra, based on scientific precision and the

Viking Line named Finnish Security Organization of the Year

Participants in the Finnish security industry have named Viking Line Security Organization of the Year 2024. According to the jury, the company has significantly improved security on its vessels both for passengers and staff and has been a trailblazer in many projects that promote security. For example, Viking Line was the first shipping company in the world to instal an automated radar system to monitor respiration in its vessels’ detention facilities.Members of the Finnish security industry and the trade publication Turvallisuus & Riskienhallinta (’Safety & Risk Management’) named Viking

Well-executed clinical introduction of EndoDrill[®] GI at Sahlgrenska University Hospital in Sweden

The cancer diagnostics company BiBBInstruments AB ("BiBB" and the “Company”), the developer of EndoDrill[®], the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first clinical tissue sampling procedures with EndoDrill[® ]GI at Sahlgrenska University Hospital in Gothenburg have been successfully completed. Expanded market studies at several hospitals in Europe and the USA are an important part of the Company's strategy and represent the first step in the launch of EndoDrill[®] GI.“It was very rewarding to be present and witness users from yet

BioStock: Curasight announces brain cancer as initial target for uTREAT

Brain cancer will be the first indication for Curasight’s uTREAT therapy. The company’s decision to choose aggressive brain cancer for a fast single indications trial is backed by promising preclinical and clinical results demonstrating the potential of its uPAR-targeted technologies in neuro-oncology. Curasight aims to begin dosing the first patient in a clinical trial by the end of the second quarter of 2025. BioStock contacted CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/11/curasight-announces-brain-cancer-as-initial-

Lappland Guldprospektering discovers a high-grade mineralized zone of 9 meters with an average of 8.5 Grams Au/ton in its initial drilling Program

Lappland Guldprospektering’s summer drilling provided valuable information through several observations of solid gold. Drill hole 4 indicated a gold-rich zone of 9 meters between 39 and 48 meters with an average grade of 8.5 g/t, including 0.5 meters at 140 g/t. This zone is part of a longer gold-mineralized position with relatively low gold content. This drill hole (no. 4) also revealed a near-surface position between 9.1 meters and 11.3 meters with a gold content of 4.5 g per ton.The drillings indicate a gold-rich zone that may be an extension of previous drilling hits. In the remaining

Interim Report Q3 2024 (January - September)

July – September 2024- Revenue MSEK 141 (157)- Order intake and Procurement Awards MSEK 95 (145)- Operating profit (EBITDA) MSEK 12.0 (19.2)- Operating profit (EBIT) MSEK 1.1 (8.3 )- Total Comprehensive income MSEK -18.5 (-2.0)- Earnings per share, before and after dilution (SEK) -0.71 (0.69)- Cash flow from operating activities MSEK 8.9 (4.1) January – September 2024- Revenue MSEK 433 (403)- Order intake and Procurement Awards MSEK 831 (541)- Operating profit (EBITDA) MSEK 40.3 (39.9)- Operating profit (EBIT) MSEK 7.8 (5.3)- Total Comprehensive income MSEK 4.7 (12.

Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas—Inherited Gastrointestinal Cancers

PHILADELPHIA (USA) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC).   The Scientific Committee of the CGA-IGC evaluated and accepted Immunovia’s abstract, which reports outcomes from the company’s model-development study, for presentation at the meeting. Immunovia’s submission was also recognized for inclusion in the Henry Lynch

There are no items matching the current filter
There are no more items matching the current filter
Back to top